Search

Part 2: the Arclight Device: frugal imaging for eyecare

In this three-part series (Click here for Part 1 and here for Part 3) Andrew Blaikie and his team explore the role and application of the Arclight Device in Imaging of the Eye. There are many different types of ophthalmic...

Congenital and paediatric cataract: Advances in diagnosis and management

Congenital and paediatric cataracts are relatively rare, although prevalence varies significantly between countries, influenced by factors such as nutrition, immunisation policy and population genetics [1]. In the UK, around 3–4 of every 10,000 babies are born with cataracts. It’s a...

Strengthening the signal: Advancing oculomics research for systemic health insights

Oculomics, the study of how ocular structure reflects systemic health, is poised to become an integral tool for predicting, triaging, and diagnosing a wide range of diseases. By analysing data from the eye, particularly the retina, healthcare providers can gain...

Retinoblastoma, CureAll and the role of global clinical, capacity strengthening and research networks

Retinoblastoma (Rb), a rare childhood eye cancer, presents a particularly compelling example of how global health partnerships can operate at the intersection of different medical disciplines, in this case: ophthalmology, oncology and public health. This article places the work of...

Diabetes and diabetic retinopathy: Changes in understanding of the disease over the last 25 years and how the UK is helping low-income countries tackle the challenges

Diabetes – a historical perspective Diabetes mellitus (DM) is a chronic disease caused by inherited and / or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. Such a deficiency results in...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Designing ophthalmology services Part 2: How do we address the queues for a clinic?

The first of this three-part series showed how systems engineering can be used to correctly diagnose and address the causes of delays in a clinic. This second article describes how to design a more productive system that meets the new...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...